Quick Answer
ASCENTAGE PHARMA GROUP INTERNATIONAL reported R&D Expense of $947.25 million for fiscal year 2024.
ASCENTAGE PHARMA GROUP INTERNATIONAL R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $947.25M | +34.0% |
| 2023 | $706.97M | -4.9% |
| 2022 | $743.10M | — |
- ASCENTAGE PHARMA GROUP INTERNATIONAL showed an increase of +34.0% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2024 period, ASCENTAGE PHARMA GROUP INTERNATIONAL’s r&d expense has grown by 27.5% (from $743.10 million to $947.25 million).
- The most recent figure is from ASCENTAGE PHARMA GROUP INTERNATIONAL’s fiscal year 2024 report (Form 20-F), filed with the SEC on April 16, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: